A-Alpha Bio Announces Collaboration With Gilead to Advance Next-Generation HIV Therapeutic Options
Summary
Under the collaboration, A-Alpha will apply its synthetic biology platform, AlphaSeq, to assess millions of interactions between potential therapeutic moieties and viral protein variants. The data generated by AlphaSeq will inform their machine learning (ML) platform, AlphaBind, to predict proteins that offer enhanced binding breadth and resistance to viral escape. A-Alpha Bio, the protein-protein interaction company, is uniquely suited to discover and optimize biologics with challenging binding requirements, such as broad cross-reactivity. “We are excited to collaborate with Gilead to advance the next generation of HIV therapies, drawing on our expertise in discovering and optimizing highly cross-reactive biologics," said David Younger, CEO and Co-founder of A-Alpha Bio. The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously.